Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated with Anifrolumab in the Early Access Programs.

Trial Identifier: D3461R00058
Sponsor: AstraZeneca
Collaborator:
CernerEnviza / Oracle
Start Date: October 2023
Primary Completion Date: June 2024
Study Completion Date: June 2024
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France Caen cedex 9, France
France DIJON Cedex, France
France Lille, France
France Paris, France
France Toulouse, France
Greece Athens, Greece
Israel Ramat Gan, Israel
Israel Tel Aviv-Yafo, Israel
Italy Pisa -PI-, Italy
Portugal Porto, Portugal
Spain Barcelona, Spain
Spain Coslada, Madrid, Spain
Spain Valladolid, Spain
United Kingdom Leeds, United Kingdom